Skip to main content
TipRanks
Go Ultimate75% OFF

Nureca Ltd. (NURECA) AI Stock Analysis

0 Followers
IN:NURECA

Nureca Ltd.

(NSE:NURECA)

Select Model
Rating:68Neutral
Price Target:INR 324.00▲(9.50% Upside)
Action:reiterated
Date:09/29/26

Nureca's score is primarily driven by robust technical momentum and a highly conservative, debt-free balance sheet. While the recent return to top-line growth and positive cash flow are encouraging fundamental strengths, the stock's stretched valuation (88.5x P/E) and remarkably thin profit margins present notable headwinds that limit the overall rating.

Positive Factors
Conservative Balance SheetVery low leverage and a large equity base reduce financial risk and preserve flexibility to fund operations or growth without heavy financing pressure. This is especially durable because it can help the company absorb earnings volatility while retaining strategic options.
Negative Factors
Thin Profit MarginsFY2026 net margin of about 1.4% and operating margin of about 4.4% leave limited room for cost increases, execution mistakes, or weaker demand. Thin profitability reduces internal funding capacity and makes earnings more sensitive to modest changes in revenue or expenses.

Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%IN:NURECA+16.96%INDA-5.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 3.02B
Dividend Yield
―
Average Volume (3M)
861
Price to Earnings (P/E)
63.8
Beta (1Y)
0.79
Revenue Growth
33.66%
EPS Growth
17.10%
Country
India
Employees
154
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Nureca Ltd. Business Overview & Revenue Model

Company Description

Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditio...

Nureca Ltd. Financial Statement Overview

Summary

Nureca features a fortress balance sheet with a negligible debt-to-equity ratio of 0.01x. Recent recoveries in revenue growth and net income are positive, though compressed profit margins (1.4% net margin) and a sluggish return on equity constrain the score.

Income Statement

60Neutral

Balance Sheet

85Very Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.74B1.47B1.10B919.28M1.11B2.56B
Gross Profit444.82M352.34M231.33M311.42M355.94M1.23B
EBITDA111.18M85.19M48.95M2.41M-79.04M632.04M
Net Income47.60M20.82M8.46M-17.94M-82.50M449.60M
Balance Sheet
Total Assets2.31B1.96B2.10B2.05B2.07B2.19B
Cash, Cash Equivalents and Short-Term Investments735.52M424.31M736.29M1.44B1.02B927.10M
Total Debt66.01M22.59M49.66M25.16M33.27M44.05M
Total Liabilities433.97M153.96M156.91M120.54M116.97M159.32M
Stockholders Equity1.88B1.81B1.94B1.93B1.95B2.03B
Cash Flow
Free Cash Flow017.45M-234.06M-37.98M98.31M-46.00M
Operating Cash Flow085.74M-190.83M-27.12M102.27M13.99M
Investing Cash Flow081.20M84.39M175.76M-164.56M-30.89M
Financing Cash Flow0-184.66M-1.69M-13.03M-15.07M-73.02M

Nureca Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price295.90

Price Trends

50DMA324.50Negative
100DMA311.04Negative
200DMA286.62Positive

Market Momentum

MACD-7.60Positive
RSI37.01Neutral
STOCH28.12Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Negative. The current price of 295.90 is below the 20-day moving average (MA) of 307.00, below the 50-day MA of 324.50, and above the 200-day MA of 286.62, indicating a neutral trend. The MACD of -7.60 indicates Positive momentum. The RSI at 37.01 is Neutral, neither overbought nor oversold. The STOCH value of 28.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NURECA.

Nureca Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:NURECA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:BLUEJETIN:BLUEJET71OutperformINR 96.53B32.40―0.23%-7.05%-21.25%
IN:NURECAIN:NURECA68NeutralINR 2.82B63.79――33.66%17.10%
IN:PGHLIN:PGHL64NeutralINR 90.83B24.06―3.84%13.04%4.60%
IN:AMRUTANJANIN:AMRUTANJAN62NeutralINR 14.87B26.05―0.95%10.68%-1.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:ZOTAIN:ZOTA45NeutralINR 39.87B-39.19―0.08%68.95%-55.82%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%40%IN:NURECAIN:AMRUTANJANIN:BLUEJETIN:PGHLIN:SANOFICONRIN:ZOTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:NURECA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:NURECANureca Ltd.295.9039.6515.47%
IN:AMRUTANJANAmrutanjan Health Care Limited515.90-173.88-25.21%
IN:BLUEJETBlue Jet Healthcare Limited517.90-36.19-6.53%
IN:PGHLProcter & Gamble Health Ltd.5503.25-116.14-2.07%
IN:SANOFICONRSanofi Consumer Healthcare India Limited3528.50-1145.36-24.51%
IN:ZOTAZota Health Care Ltd.1314.50-369.13-21.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026